Nanoconfined 2LiBH4eMgH2eTiCl3 in carbon aerogel scaffold for reversible hydrogen storage

Nanoconfinement of 2LiBH4–MgH2–TiCl3 in resorcinol–formaldehyde carbon aerogel scaffold (RF–CAS) for reversible hydrogen storage applications is proposed. RF–CAS is encapsulated with approximately 1.6 wt. % TiCl3 by solution impregnation technique, and it is further nanoconfined with bulk 2LiBH4–MgH2 via melt infiltration. Faster dehydrogenation kinetics is obtained after TiCl3 impregnation, for example, nanoconfined 2LiBH4–MgH2–TiCl3 requires ∼1 and 4.5 h, respectively, to release 95% of the total hydrogen content during the 1st and 2nd cycles, while nanoconfined 2LiBH4–MgH2 (∼2.5 and 7 h, respectively) and bulk material (∼23 and 22 h, respectively) take considerably longer. Moreover, 95–98.6% of the theoretical H2 storage capacity (3.6–3.75 wt. % H2) is reproduced after four hydrogen release and uptake cycles of the nanoconfined 2LiBH4–MgH2–TiCl3. The reversibility of this hydrogen storage material is confirmed by the formation of LiBH4 and MgH2 after rehydrogenation using FTIR and SR-PXD techniques, respectively.Fil: Gosalawit Utke, Rapee. Helmholtz-Zentrum Geesthacht; Alemania. Suranaree University of Technology; TailandiaFil: Milanese, Chiara. Università degli studi di Pavia; ItaliaFil: Javadian, Payam. University Aarhus; DinamarcaFil: Jepsen, Julian. Helmholtz-Zentrum Geesthacht; AlemaniaFil: Laipple, Daniel. Helmholtz-Zentrum Geesthacht; AlemaniaFil: Karmi, Fahim. Helmholtz-Zentrum Geesthacht; AlemaniaFil: Puszkiel, Julián Atilio. Helmholtz-Zentrum Geesthacht; Alemania. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Jensen, Torben R.. University Aarhus; DinamarcaFil: Marini, Amedeo. Università degli studi di Pavia; ItaliaFil: Klassen, Thomas. Helmholtz-Zentrum Geesthacht; AlemaniaFil: Dornheim, Martin. Helmholtz-Zentrum Geesthacht; Alemani

DNA testing and domestic dogs

There are currently about 80 different DNA tests available for mutations that are associated with inherited disease in the domestic dog, and as the tools available with which to dissect the canine genome become increasingly sophisticated, this number can be expected to rise dramatically over the next few years. With unrelenting media pressure focused firmly on the health of the purebred domestic dog, veterinarians and dog breeders are turning increasingly to DNA tests to ensure the health of their dogs. It is ultimately the responsibility of the scientists who identify disease-associated genetic variants to make sensible choices about which discoveries are appropriate to develop into commercially available DNA tests for the lay dog breeder, who needs to balance the need to improve the genetic health of their breed with the need to maintain genetic diversity. This review discusses some of the factors that should be considered along the route from mutation discovery to DNA test and some representative examples of DNA tests currently available

Mutations in the SLC2A9 Gene Cause Hyperuricosuria and Hyperuricemia in the Dog

Allantoin is the end product of purine catabolism in all mammals except humans, great apes, and one breed of dog, the Dalmatian. Humans and Dalmatian dogs produce uric acid during purine degradation, which leads to elevated levels of uric acid in blood and urine and can result in significant diseases in both species. The defect in Dalmatians results from inefficient transport of uric acid in both the liver and renal proximal tubules. Hyperuricosuria and hyperuricemia (huu) is a simple autosomal recessive trait for which all Dalmatian dogs are homozygous. Therefore, in order to map the locus, an interbreed backcross was used. Linkage mapping localized the huu trait to CFA03, which excluded the obvious urate transporter 1 gene, SLC22A12. Positional cloning placed the locus in a minimal interval of 2.5 Mb with a LOD score of 17.45. A critical interval of 333 kb containing only four genes was homozygous in all Dalmatians. Sequence and expression analyses of the SLC2A9 gene indicated three possible mutations, a missense mutation (G616T;C188F) and two promoter mutations that together appear to reduce the expression levels of one of the isoforms. The missense mutation is associated with hyperuricosuria in the Dalmatian, while the promoter SNPs occur in other unaffected breeds of dog. Verification of the causative nature of these changes was obtained when hyperuricosuric dogs from several other breeds were found to possess the same combination of mutations as found in the Dalmatian. The Dalmatian dog model of hyperuricosuria and hyperuricemia underscores the importance of SLC2A9 for uric acid transport in mammals

Criteria for the selection of complementary private health insurance: the experience of a large organisation in Iran

Background Expenses related to employee's health benefit packages are rising. Hence, organisations are looking for complementary health financing arrangements to provide more financial protection for employees. This study aims to develop criteria to choose the most appropriate complementary health insurance company based on the experience of a large organisation in Iran. Methods This study was conducted in 2021 in Iran, in the Foundation of Martyrs and Veterans Affairs to find as many applicable criteria as possible. To develop a comprehensive list of criteria, we used triangulation in data sources, including review of relevant national and international documents, in-depth interviews of key informants, focus group discussion, and examining similar but unpublished checklists used by other organisations in Iran. The list of criteria was prioritised during focus group discussions. We used the best-worst method as a multi-criteria decision making method and a qualitative consensus among the key informants to value the importance of each of the finalised criteria. Findings Out of 85 criteria, we selected 28 criteria to choose an insurer for implementing complementary private health insurance. The finalised criteria were fell into six domains: (i) Previous experience of the applicants; (ii) Communication with clients; (iii) Financial status; (iv) Health care providers' network; (v) Technical infrastructure and workforce; (vi) and Process of reviewing claims and reimbursement. Conclusion We propose a quantitative decision-making checklist to choose the best complimentary private health insurance provider. We invite colleagues to utilise, adapt, modify, or develop these criteria to suit their organisational needs. This checklist can be applied in any low- and middle-income country where the industry of complementary health insurance is blooming